Anti-tumour necrosis factor monoclonal antibody (3SBio)

人源化抗人TNFα单抗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-tumour necrosis factor monoclonal antibody (3SBio)
Drug Alias Name人源化抗人TNFα单抗注射液(CHO细胞)Humanised TNF alpha monoclonal antibodyAPX-001 (3SBio)SSS-07
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor inhibitors
TargetsTumor necrosis factor
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEpitomics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenyang Sunshine Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A